- £11.35m
- £6.62m
- £5.77m
- 22
- 38
- 69
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.92 | ||
| Price to Tang. Book | 1.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.08% | ||
| Return on Equity | -13.85% | ||
| Operating Margin | -23.23% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 9.53 | 9.19 | 8.64 | 6.67 | 5.77 | 6.3 | 6.9 | -5.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +117.33 | +49.5 | -30.44 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Directors
- Charles Spicer NEC (51)
- Giulio Cerroni CEO (59)
- Grant Nash CFO (44)
- John Bradshaw NED
- Katherine Rogers NED (55)
- Mark Warne NID (45)
- Last Annual
- September 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 28th, 1995
- Public Since
- September 4th, 2013
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 92,668,598
- Address
- 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN
- Web
- https://ixico.com/
- Phone
- +44 2037637499
- Auditors
- Grant Thornton UK LLP
Latest News for IXI
Upcoming Events for IXI
Full Year 2025 IXICO PLC Earnings Release
IXICO PLC Annual Shareholders Meeting
Similar to IXI
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 03:23 UTC, shares in IXICO are trading at 12.25p. This share price information is delayed by 15 minutes.
Shares in IXICO last closed at 12.25p and the price had moved by +28.95% over the past 365 days. In terms of relative price strength the IXICO share price has outperformed the FTSE All Share Index by +18.3% over the past year.
The overall consensus recommendation for IXICO is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIXICO does not currently pay a dividend.
IXICO does not currently pay a dividend.
IXICO does not currently pay a dividend.
To buy shares in IXICO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 12.25p, shares in IXICO had a market capitalisation of £11.35m.
Here are the trading details for IXICO:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: IXI
Based on an overall assessment of its quality, value and momentum IXICO is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in IXICO is 24.00p. That is 95.92% above the last closing price of 12.25p.
Analysts covering IXICO currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IXICO. Over the past six months, its share price has underperformed the FTSE All Share Index by -2.42%.
As of the last closing price of 12.25p, shares in IXICO were trading +15.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IXICO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 12.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IXICO's management team is headed by:
- Charles Spicer - NEC
- Giulio Cerroni - CEO
- Grant Nash - CFO
- John Bradshaw - NED
- Katherine Rogers - NED
- Mark Warne - NID